Rutherford, G. W., & Horvath, H. (2016). Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review. PLoS One.
Styl cytowania ChicagoRutherford, George W., i Hacsi Horvath. "Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors Versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People With HIV: A Systematic Review." PLoS One 2016.
Styl cytowania MLARutherford, George W., i Hacsi Horvath. "Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors Versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People With HIV: A Systematic Review." PLoS One 2016.